Gene Therapy, 0969-7128

Journal

More filtering options
  1. 2019
  2. GDNF-mediated rescue of the nigrostriatal system depends on the degree of degeneration

    Luis Quintino, Martino Avallone, Emil Brännstrom, Patrick Kavanagh, Marcus Lockowandt, Patricia Garcia Jareño, Ludivine S. Breger & Cecilia Lundberg, 2019, In: Gene Therapy. 26, 1-2, p. 57-64

    Research output: Contribution to journalArticle

  3. Unilateral ex vivo gene therapy by GDNF in epileptic rats

    Avtandil Nanobashvili, Esbjörn Melin, Dwaine Emerich, Jens Tornøe, Michele Simonato, Lars Wahlberg & Merab Kokaia, 2019, In: Gene Therapy. 26, 3-4, p. 65-74

    Research output: Contribution to journalArticle

  4. 2016
  5. DREADDs suppress seizure-like activity in a mouse model of pharmacoresistant epileptic brain tissue

    N. Avaliani, M. Andersson, A. H. Runegaard, D. Woldbye & M. Kokaia, 2016 Oct 1, In: Gene Therapy. 23, 10, p. 760-766 7 p.

    Research output: Contribution to journalArticle

  6. 2009
  7. Intravitreal delivery of AAV8 retinoschisin results in cell type-specific gene expression and retinal rescue in the Rs1-KO mouse

    T K Park, Z Wu, S Kjellstrom, Yong Zeng, Ronald A Bush, P A Sieving & Peter Colosi, 2009 Jul, In: Gene Therapy. 16, 7, p. 916-26 11 p.

    Research output: Contribution to journalArticle

  8. 2007
  9. Cell-specific and efficient expression in mouse and human B cells by a novel hybrid immunoglobulin promoter in a lentiviral vector

    K. L. Laurie, M. P. Blundell, H. E. Baxendale, S. J. Howe, J. Sinclair, W. Qasim, U Brunsberg, A. J. Thrasher, Rikard Holmdahl & K Gustafsson, 2007, In: Gene Therapy. 14, 23, p. 1623-1631

    Research output: Contribution to journalArticle

  10. Drosophila deoxyribonucleoside kinase mutants with enhanced ability to phosphorylate purine analogs

    W. Knecht, Elzbieta Rozpedowska, C. Le Breton, M. Willer, Z. Gojkovic, Michael Sandrini, T. Joergensen, L. Hasholt, B. Munch-Petersen & Jure Piskur, 2007, In: Gene Therapy. 14, 17, p. 1278-1286

    Research output: Contribution to journalArticle

  11. 2006
  12. Efficient transduction of neurons using Ross River glycoprotein-pseudotyped lentiviral vectors.

    Johan Jakobsson, Troels Tolstrup Nielsen, Karin Staflin, Biljana Georgievska & Cecilia Lundberg, 2006, In: Gene Therapy. 13, 12, p. 966-973

    Research output: Contribution to journalArticle

  13. 2005
  14. Lentiviral vector-mediated gene transfer in adult mouse photoreceptors is impaired by the presence of a physical barrier

    O Gruter, C Kostic, SV Crippa, Maria Thereza Perez, L Zografos, DF Schorderet, FL Munier & Y Arsenijevic, 2005, In: Gene Therapy. 12, 11, p. 942-947

    Research output: Contribution to journalArticle

  15. Parkinson's disease: Viral vector delivery of parkin generates model results in rats.

    Deniz Kirik & Anders Björklund, 2005, In: Gene Therapy. 12, 9, p. 727-729

    Research output: Contribution to journalDebate/Note/Editorial

  16. Stable, long-term label opens doors for gene therapy.

    Cecilia Lundberg, 2005, In: Gene Therapy. 12, 3, p. 195-195

    Research output: Contribution to journalDebate/Note/Editorial

  17. 2002
  18. Evaluation of Tet-on system to avoid transgene downregulation in ex vivo gene transfer to the CNS

    J Johansen, C Rosenblad, Kim Andsberg, A Moller, Cecilia Lundberg, Anders Björklund & TE Johansen, 2002, In: Gene Therapy. 9, 19, p. 1291-1301

    Research output: Contribution to journalArticle

  19. 1999
  20. BDNF gene transfer to the mammalian brain using CNS-derived neural precursors

    F. T. Rubio, Z. Kokaia, A. Del Arco, M. I. García-Simón, E. Y. Snyder, O. Lindvall, J. Satrústegui & A. Martínez-Serrano, 1999 Jan 1, In: Gene Therapy. 6, 11, p. 1851-1866 16 p.

    Research output: Contribution to journalArticle

  21. 1996
  22. Targeting of retroviral vectors through protease-substrate interactions

    B H Nilson, F J Morling, F L Cosset & S J Russell, 1996 Apr, In: Gene Therapy. 3, 4, p. 280-286

    Research output: Contribution to journalArticle